Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

888 shares rise as Gambling Commission finishes licence review

(Sharecast News) - Gambling operator 888 Holdings announced on Friday that it has received notice from the Gambling Commission that it had completed its review of the group's operating licences under the Gambling Act 2005. The London-listed company said the review, initiated on 14 July, ended without any imposition of licence conditions, financial penalties, or other remedies.

It said the Gambling Commission expressed 888 Holdings had effectively managed and mitigated satisfaction risks to the licensing objectives.

At the time it launched its review, the Gambling Commission said it was in response to FS Holdings acquiring a stake of 888, s well as the planned appointment of ex-GVC executives Kenny Alexander, Lee Feldman and Stephen Morana.

Those appointments were not made in light of the review, however.

At 1023 GMT, shares in 888 Holdings were up 2.88% at 88.89p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.